舒肝解郁胶囊治疗寻常型银屑病的临床研究

发布时间：2018-03-07 20:18

本文选题：舒肝解郁胶囊　切入点：银屑病　出处：《中国临床药理学杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的观察舒肝解郁胶囊治疗寻常型银屑病的临床疗效及安全性。方法将60例进展期寻常型银屑病患者随机分成对照组30例和试验组30例,另取健康志愿者30例作为健康对照组。对照组予以口服复方甘草酸苷片每次50 mg tid,外用卤米松/三氯生乳膏和卡泊三醇软膏涂擦于患处,bid。试验组在对照组治疗的基础上,予以口服舒肝解郁胶囊每次0.72 g tid。2组患者1个疗程均为4周,共治疗4个疗程。比较2组患者的临床疗效和药物不良反应的发生情况。并比较3组患者的汉密尔顿抑郁量表(HAMD)评分、汉密尔顿焦虑量表(HAMA)评分、血清中去甲肾上腺素(NE)、多巴胺(DA)及5-羟色胺(5-HT)的含量。结果治疗后,试验组和对照组的总有效率分别为96.67%(29/30例)和66.67%(20/30例),差异有统计学意义(P0.01)。治疗前,试验组、对照组和健康对照组的HAMD评分分别为(21.55±5.62),(20.93±5.57),(8.18±1.98)分;HAMA评分分别为(17.69±4.78),(18.04±4.14),(7.44±2.12)分;NE分别为(6.95±2.31),(6.78±2.26),(2.09±1.11)μg·g~(-1);DA分别为(8.02±2.22),(8.16±2.31),(4.68±1.34)μg·g~(-1);5-HT分别为(62.67±21.18),(61.88±21.55),(21.15±8.66)μg·g~(-1),试验组、对照组的上述指标与健康对照组比较差异均有统计学意义(P0.01)。治疗后,试验组和对照组的HAMD评分分别为(13.46±3.65),(18.89±3.86)分;HAMA评分分别为(10.75±2.83),(16.64±3.59)分;NE分别为(3.25±2.16),(4.78±1.32)μg·g~(-1);DA分别为(4.65±1.42),(6.88±2.19)μg·g~(-1);5-HT分别为(32.34±10.95),(46.65±20.26)μg·g~(-1),差异均有统计学意义(P0.01)。试验组和对照组治疗期间未发生药物不良反应。结论舒肝解郁胶囊治疗寻常型银屑病的临床疗效显著,能有效改善患者的精神状态,调节外周血单胺类神经递质水平,且安全性较高。
[Abstract]:Objective to observe the clinical efficacy and safety of Shugan Jieyu capsule in the treatment of psoriasis vulgaris. Methods 60 patients with advanced psoriasis vulgaris were randomly divided into control group (n = 30) and experimental group (n = 30). Another 30 healthy volunteers were taken as the healthy control group. The control group was given oral compound glycyrrhizin tablets 50 mg tid each time, and was applied with halomethasone / triclosan cream and carpotriol ointment to the affected area. The experimental group was treated on the basis of the control group. The patients in the 0.72 g tid.2 group were treated with Shugan Jie Yu capsule for 4 weeks. The clinical efficacy and adverse drug reactions of the two groups were compared, and the scores of Hamilton Depression scale (Hamd), Hamilton anxiety scale (Hamilton anxiety scale) and Hamilton anxiety scale (Hama) were compared among the 3 groups. Results after treatment, the total effective rates of the test group and the control group were 96.67 / 29 / 30) and 66.67 / 20 / 30 cases respectively, the difference was statistically significant (P 0.01). Before treatment, the total effective rates of the experimental group and the control group were 96.67 / 29 / 30 and 66.67 / 20 / 30, respectively. The HAMD scores of the control group and the healthy control group were 21.55 卤5.62 卤5.62 卤8.18 卤1.98) and 17.69 卤4.787.44 卤2.12, respectively. The HAMD scores of the control group and the healthy control group were 6.95 卤2.31 卤2.39 卤2.26 卤2.09 卤1.11 渭 g 路g / g, respectively. The difference between the control group and the control group was 8.16 卤2.31 (4.68 卤1.34) 渭 g 路g ~ (-1) (P < 0.01). The HAMD scores of the test group and the control group were 13.46 卤3.65 卤18.89 卤3.86) and the Hama scores were 10.75 卤2.83 卤16.64 卤3.59) respectively. The scores of NE were 3.25 卤2.16 卤4.78 卤1.32 渭 g 路g-1 DA, respectively, 4.65 卤1.42 卤2.19 渭 g 路g 路g ~ (-1) of Hama and 32.34 卤10.95 ~ (65 卤20.26) 渭 g 路g 路L ~ (-1) of Hama, respectively. There was no significant difference between the experimental group and the control group in adverse drug reactions during the treatment period. The clinical effect of Shugan Jie Yu capsule on psoriasis vulgaris was remarkable. It can effectively improve the mental state of patients and regulate the level of monoamine neurotransmitters in peripheral blood.
【作者单位】：浙江中医药大学附属第一医院精神卫生科;浙江中医药大学附属第一医院皮肤性病科;
【基金】：浙江省自然科学基金资助项目(Y14H110005) 浙江省中医药科技课题基金资助项目(2011ZB046)
【分类号】：R758.63

【参考文献】